Cephalic arch stenosis in autogenous haemodialysis fistulas: treatment with the viabahn stent-graft
| Autor: | Andrew Shawyer, Arun Iyer, Magdi Yaqoob, Martin Raftery, Mark Blunden, Girish Namagondlu, Nicos Fotiadis |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Fistula Prosthesis Design Risk Assessment End stage renal disease Cohort Studies Arteriovenous Shunt Surgical Renal Dialysis Angioplasty Confidence Intervals Medicine Humans Radiology Nuclear Medicine and imaging Vein Vascular Patency Aged Retrospective Studies business.industry Graft Survival Graft Occlusion Vascular Stent Retrospective cohort study Middle Aged medicine.disease Surgery Radiography Stenosis medicine.anatomical_structure Treatment Outcome Kidney Failure Chronic Female Stents Radiology Hemodialysis Patient Safety Jugular Veins Cardiology and Cardiovascular Medicine business Angioplasty Balloon Follow-Up Studies |
| Zdroj: | Cardiovascular and interventional radiology. 36(1) |
| ISSN: | 1432-086X |
| Popis: | Cephalic arch stenosis (CAS) is an important and common cause of dysfunction in autogenous haemodialysis fistulas that requires multiple reinterventions and aggressive surveillance. We evaluated the safety and efficacy of the Viabahn stent-graft for the management of CAS. Between April 2005 and October 2011, 11 consecutive patients [four men and seven women (mean age 56.7 years)] with CAS and dysfunctional fistulas were treated with insertion of 11 Viabahn stent-grafts. Six stent-grafts were inserted due to residual stenosis after angioplasty and five for fistuloplasty-induced rupture. No patient was lost to follow-up. The technical and clinical success rate was 100 %. Primary access patency rates were 81.8 % [95 % confidence interval (CI) 0.482–0.977] at 6 months and 72.7 % (95 % CI 0.390–0.939) at 12 months. Secondary access patency rates were 90.9 % at 6 months (95 % CI 0.587–0.997). There were no procedure-related complications. Mean follow-up was 543.8 days (range 156–2,282). The use of the Viabahn stent-graft in the management of CAS is technically feasible and, in this small series, showed patency rates that compare favorably with historical data of angioplasty and bare stents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink